Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 18/20 | 0.39 |
| ▸ | TNF | P01375 | 3/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26094347 | 0.80 | IL1B (0.42) | IL1BTNFNLRP3 | |
| SCHEMBL3199415 | 0.72 | ERN1 (0.49) | MEN1MAPTKMT2AERN1 | |
| SCHEMBL31048131 | 0.68 | IL1B (0.37) | IL1BTNFNLRP3 | |
| SCHEMBL26093177 | 0.68 | ERN1 (0.44) | MEN1MAPTKMT2AERN1 | |
| SCHEMBL31166554 | 0.68 | ERN1 (0.44) | MEN1MAPTKMT2AERN1 | |
| SCHEMBL22695045 | 0.63 | IL1B (0.61) | IL1BTNFNLRP3 | |
| SCHEMBL31233716 | 0.62 | IL1B (0.51) | IL1BTNFNLRP3 | |
| SCHEMBL31404979 | 0.62 | IL1B (0.58) | IL1BTNFNLRP3 | |
| SCHEMBL8159248 | 0.62 | ALDH1A1 (0.43) | MEN1MAPTKMT2A | |
| SCHEMBL22695042 | 0.60 | IL1B (0.57) | IL1BTNFNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-08-22 | — | — | US | disclosed |
| CN-118119626-A | Fused bicyclic heteroaryl compounds useful as NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | IL1B 31/4885TNF 2078/4885NLRP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.